BD Announces Global Commercial Release Of New BD FACSDiscover S8 Cell Sorters

RTTNews | 587 dias atrás
BD Announces Global Commercial Release Of New BD FACSDiscover S8 Cell Sorters

(RTTNews) - Medical technology company BD or Becton, Dickinson and Co. (BDX) announced Friday the global commercial release of new cell sorters that will enable more researchers in a broader range of fields, including cell biology, cancer research and immunology, to reveal insights that were previously invisible in traditional flow cytometry experiments.

The new BD FACSDiscover S8 Cell Sorters feature BD CellView Image Technology, profiled on the cover of the journal Science in 2022, and BD SpectralFX Technology — bringing to market breakthrough innovations in real-time imaging and spectral flow cytometry.

The three- and four-laser additions to the BD FACSDiscover S8 Cell Sorter family complement the five-laser instrument launched last year and provide scientists greater access, options, and flexibility to incorporate real-time imaging and spectral cell sorting technology in their labs.

Using the FACSDiscover S8 Cell Sorters, researchers can confirm complex biological and spatial insights in real time, obtain individual cell images and isolate desired cells based on visual characteristics at high speeds, all within a simplified and easy to use workflow.

BD CellView Image Technology improves sort and sample quality, bringing confidence to biological results and saving researchers time and cost in their downstream applications.

This expedited time to insight expands capabilities for researchers to transform research and cell-based therapeutic development across numerous fields in drug discovery, immuno-oncology and genomics.

Etiquetas: BDX
read more
BD Recalls ChloraPrep Clear 1 ML Applicators

BD Recalls ChloraPrep Clear 1 ML Applicators

Medical technology company Becton, Dickinson and Co. or BD has recalled one lot of ChloraPrep Clear 1 mL Applicators citing potential fungal contamination, the U.S. Food and Drug Administration said. Under certain environmental conditions, the contamination allows the growth of Aspergillus penicillioides within the packaging.
RTTNews | 267 dias atrás
Becton, Dickinson Boosts FY24 Ad, EPS Outlook - Update

Becton, Dickinson Boosts FY24 Ad, EPS Outlook - Update

While reporting financial results for the third quarter on Thursday, medical technology company Becton, Dickinson and Co. (BDX) raised its adjusted earnings guidance for fiscal 2024, while trimming annual revenue outlook.
RTTNews | 469 dias atrás
BD Gets FDA 510(k) Clearance For Fingertip Blood Collection Device

BD Gets FDA 510(k) Clearance For Fingertip Blood Collection Device

Medical technology company Becton, Dickinson and Co. or BD (BDX) announced Thursday it has received 510(k) clearances from the U.S. Federal Drug Administration (FDA) for a novel blood collection device that obtains blood samples from a fingerstick that produce lab-quality results for some of the most commonly ordered blood tests.
RTTNews | 707 dias atrás
Becton, Dickinson Boosts FY23 Outlook - Update

Becton, Dickinson Boosts FY23 Outlook - Update

While reporting financial results for the second quarter on Thursday, medical technology company Becton, Dickinson and Co. (BDX) raised its adjusted earnings and revenue outlook for fiscal 2023.
RTTNews | 924 dias atrás
Becton, Dickinson Boosts FY23 Outlook - Update

Becton, Dickinson Boosts FY23 Outlook - Update

While reporting financial results for the first quarter on Thursday, medical technology company Becton, Dickinson and Co. or BD (BDX) raised its adjusted earnings and revenue outlook for fiscal 2023.
RTTNews | 1015 dias atrás
Disney Q4 Profit Beats Street, Revenues Miss; Sees Adj. EPS Growth, Plans $7 Bln Buyback; Stock Down

Disney Q4 Profit Beats Street, Revenues Miss; Sees Adj. EPS Growth, Plans $7 Bln Buyback; Stock Down

Shares of Walt Disney Co. were losing around 4 percent in the pre-market activity on Thursday after the media and entertainment major reported nearly flat revenues in its fourth quarter below market estimates, even though profit beat the Street. Further, the firm said it expects double digit year-over-year growth in adjusted earnings per share for fiscal 2026 and 2027, and targets doubling share
RTTNews | 1 h 9 min atrás